PDSB beat EPS expectations by 16.53%
May 14, 2025, 10:36 PM
0.00%
What does PDSB do
PDS Biotechnology, based in Princeton, New Jersey, develops clinical-stage immunotherapies for various cancers, including its lead product PDS0101, which targets HPV16. The company went public on October 1, 2015, and has 25 employees.
PDS Biotechnology (PDSB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, PDS Biotechnology's actual EPS was -$0.21, beating the estimate of -$0.25 per share, resulting in a 16.53% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.